Are Peptides Legal in Florida? A Plain-Language Overview

“Are peptides legal in Florida?” sounds like a yes-or-no question. The honest answer depends on which peptide it is, how it was made and who is selling it. This guide walks through the main federal and Florida rules in plain language, with dates, because several of them changed in 2026. This page is general information, not legal advice. For questions about your own situation, talk to a Florida-licensed attorney.

Why the answer depends on the product

“Peptide” covers three very different kinds of products:

• FDA-approved drugs. These went through FDA review for specific uses and need a prescription. Semaglutide (Wegovy) and tirzepatide (Zepbound) are examples.¹²
• Compounded drugs. A licensed pharmacy mixes these for a patient. Compounded drugs are not FDA-approved. Federal law excuses them from the approval process only when certain conditions are met.³
• “Research use only” products. These are sold online, often as powders in vials. They are neither approved drugs nor medicines compounded for a patient.

Each group follows different rules. So the first useful question is: which kind of product is this?

Compounding rules: 503A, 503B and FDA’s lists

Federal law has two lanes for compounding:

• 503A pharmacies are traditional, state-licensed pharmacies (and licensed physicians) that compound for individual patients. They may use a raw “bulk” ingredient only if it has an official quality standard (a USP or NF monograph), is part of an FDA-approved drug, or is on FDA’s 503A bulks list. FDA adds substances to that list through formal rulemaking.⁴
• 503B outsourcing facilities make larger batches. They may compound from bulk only if the substance is on a separate 503B bulks list or the drug is on FDA’s shortage list.⁵

While the lists are being built, FDA sorts nominated substances into categories. In Category 1, FDA does not intend to act against compounders while it decides. Category 2 means FDA has identified significant safety risks and would consider taking action. Category 3 means there is not enough information to evaluate. Substances nominated on or after January 7, 2025, are not placed in any category.⁴

Many popular peptides were once in Category 2. By April 22, 2026, the nominations for most of them had been withdrawn, including BPC-157, TB-500, MOTS-c, epitalon, semax and KPV. FDA still lists its safety concerns for them, such as possible immune reactions and little or no human safety data.⁶ A withdrawn nomination is not an approval. Some peptides remain in Category 2. Ipamorelin, for example, is still on FDA’s significant-safety-risk list for outsourcing facilities (503B), while its pharmacy (503A) nomination was withdrawn.⁶

The 2026 advisory vote and the HHS draft policy

In July 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A bulks list: BPC-157, KPV, TB-500 and MOTS-c on July 23, and emideltide, semax and epitalon on July 24.⁷ FDA’s own reviewers recommended against adding BPC-157. They found no studies that gave it to people by the proposed routes.⁸

The committee narrowly voted to recommend adding BPC-157, KPV and TB-500 anyway. That vote was reported as 8–6 with 1 abstention, and the MOTS-c vote as 7–5 with 2 abstentions.⁹ The vote is not binding, and any change requires formal rulemaking.⁹ FDA has posted no minutes or final decision.⁷

On October 30, 2026, the U.S. Department of Health and Human Services (HHS) published a notice about six of these peptides. According to law-firm summaries of the draft, they are BPC-157, TB-500, KPV, MOTS-c, epitalon and semax, each limited to certain forms.¹⁰ As of 13 Nov 2026, HHS has published a draft, non-binding policy saying it does not intend to take enforcement action against licensed pharmacies compounding these peptides in certain forms.¹¹ This is not FDA approval, and FDA has not added them to its official list.¹¹⁷

The notice says HHS may revisit the policy if safety or quality problems arise. It names only state-licensed pharmacies, federal facilities and licensed physicians.¹¹ One law firm reports that 503B outsourcing facilities are not covered.¹⁰ Public comments closed on 13 Nov 2026. As of November 13, 2026, a final policy had not been published. Check the Federal Register notice for updates.¹¹

“Research use only” products

In an August 2026 warning letter to a Sarasota, Florida company, FDA said that “for research use only” and “not for human or veterinary use” labels did not control. The seller’s website showed the products were meant for people. FDA also treated the sale of bacteriostatic water, used to mix powders for injection, as evidence that the products were meant to be injected. FDA called the company’s semaglutide, tirzepatide, retatrutide, SS-31, tesamorelin and PT-141 products unapproved new drugs.¹² Our guide to research chemical peptide risks covers the safety side.

Florida rules: telehealth, licenses and open questions

Florida adds its own layer on top of federal law.

• Telehealth standard of care. Telehealth providers must meet the same standard as in-person care. A video evaluation that is enough to diagnose and treat can take the place of an in-person exam. Schedule II controlled substances may not be prescribed by telehealth except in four listed situations.¹³
• Who may treat you by telehealth. The provider must hold a Florida license or certification, a license under a multistate compact Florida belongs to, or a Florida out-of-state telehealth registration. E-mail and fax alone are not telehealth. Registered out-of-state providers may not open a Florida office or see patients in person, and their websites must link to the state’s registry.¹³
• Pharmacies. Under the same law, registered out-of-state pharmacists must dispense to Florida patients through pharmacies with a Florida permit or a nonresident registration or permit.¹³ We did not review the Florida Board of Pharmacy’s permit and compounding rules in detail. Ask which pharmacy will fill your prescription, look up its license, and contact the Florida Board of Pharmacy with questions.
• License checks. The Florida Department of Health runs a free search for practitioner and pharmacy licenses and discipline records.¹⁴
• Not covered by our research. We did not review Florida’s prescribing scope for nurse practitioners (APRNs) and physician assistants (PAs), or Florida’s rules for medical spas and medical director supervision. Ask the provider who is prescribing and who supervises, and check with the Florida Department of Health’s licensing boards if you have questions.

Questions to ask before you start

• Is this an FDA-approved drug, a compounded medicine or something else?
• If it is compounded, which pharmacy makes it? Is it a 503A pharmacy or a 503B outsourcing facility?
• Where does this peptide stand on FDA’s category lists, and has that changed since the HHS draft policy?
• Who is the prescriber, and does their Florida license check out?

Our checklist on how to vet a peptide clinic goes further, and compounded vs. FDA-approved peptides explains compounding in more depth. When in doubt, ask a licensed provider for medical answers and a Florida-licensed attorney for legal ones. See also our disclaimer.